ALVO Alvotech
Debt Financing ·
Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025.
Alvotech priced 22,666,667 shares at $3.750, below its $4.24 Nasdaq close on June 15, and a private placement of 17,826,666 shares to European investors is set to add about $66.85 million.
Alvotech is a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines. It was founded in 2013 in Reykjavik, Iceland, and conducts its business through its wholly owned subsidiary, Alvotech hf. The company says it has invested over $2 billion to build a platform for developing and manufacturing biosimilars at scale. It licenses its biosimilars intellectual property to commercialization partners in exchange for development and commercialization milestone payments and royalties on sales. It has five approved products and thirty product candidates in its pipeline, targeting autoimmune, eye, respiratory and hematological diseases, as well as cancer. Its approved biosimilars include AVT02, a biosimilar to Humira (adalimumab), AVT04, a biosimilar to Stelara (ustekinumab), AVT05, a biosimilar to Simponi (golimumab), and AVT06, a biosimilar to Eylea (aflibercept). Its stated mission is broadening the availability and accessibility of biosimilars, and it says its platform may allow expansion into other healthcare product areas such as respiratory and primary care products.
| Product or program | What it is | Stage |
|---|---|---|
| AVT02 | Biosimilar to Humira (adalimumab) | approved in various major markets, including the U.S. |
| AVT04 | Biosimilar to Stelara (ustekinumab) | approved in various major markets, including the U.S. and Japan |
| AVT05 | Biosimilar to Simponi (golimumab) | approved for marketing in the UK, European Economic Area and Japan |
| AVT06 | Biosimilar to Eylea (aflibercept) | approved for marketing in the UK, European Economic Area and Japan |
Our latest story on this, dated Jun 15, 2026: "Alvotech launches $125 million share sale, then prices 22,666,667 shares at $3.750". The story links the filing or release it is based on. Read the story.
Alvotech trades under the ticker ALVO on NASDAQ.
Alvotech is listed on NASDAQ. Our directory also records these other listings: GETTEX:Z45; LS:A3DK8U; LSX:A3DK8U; OMXICE:ALVO; OMXSTO:ALVO_SDB.
The SEC Central Index Key (CIK) for Alvotech is 1898416. Its filings are on SEC EDGAR.
312,021,375 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31.
Our directory records Alvotech under Luxembourg.
Our directory classifies Alvotech as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Alvotech is LU2458332611.
aibio.space lists Alvotech among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as N4.
Alvotech is a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines. It was founded in 2013 in Reykjavik, Iceland, and conducts its business through its wholly owned subsidiary, Alvotech hf.
AVT02: Biosimilar to Humira (adalimumab) Stage: approved in various major markets, including the U.S..
AVT04: Biosimilar to Stelara (ustekinumab) Stage: approved in various major markets, including the U.S. and Japan.
Our latest story on Alvotech, dated Jul 1, 2026: "Alvotech secures $75 million term loan from GoldenTree funds". Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025. Source.
Our latest debt story, dated Jul 1, 2026: "Alvotech secures $75 million term loan from GoldenTree funds". Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025. Source.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio